AVE8062: a new combretastatin derivative vascular disrupting agent

Bibliography

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-20
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Leeson PA, Bayés M. Bevacizumab oncolytic. Drugs Future 2002;27:625-32
   Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27
   PubMed Web of Science ®Google Scholar
• Hinnen P, Falms E. Vascular disrupting agents in clinical developments. Br J Cancer 2007;96:1159-65
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9
   PubMed Web of Science ®Google Scholar
• Kakolyris S, Fox S, Koukourakis M, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 2000;82:844-51
   PubMed Web of Science ®Google Scholar
• Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001;84:1354-62
   PubMed Web of Science ®Google Scholar
• Dark GD, Sally A, Vivien E, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. The tumoral vascular targeting agent Combretastatin-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-9
   PubMed Web of Science ®Google Scholar
• Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22
   PubMed Web of Science ®Google Scholar
• Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999;43:1111-23
   PubMed Web of Science ®Google Scholar
• Lominadze D, Mchediishvili G. Red blood cell behavior at low flow rate in microvessels. Microvasc Res 1999;58:187-9
   PubMed Web of Science ®Google Scholar
• Prise VE, Honess DJ, Stratford MRL, et al. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinical relevant doses. Int J Oncol 2002;21:717-26
   PubMed Web of Science ®Google Scholar
• Alexander JS, Hechtman HB, Shepro D. Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium. Biochem Biophys Res Commun 1987;143:152-8
   PubMed Web of Science ®Google Scholar
• Brooks AC, Kanthou C, Cook IH, et al. The vascular targeting agent combretastatin A-4-phosphate induces neutrophils recruitment to endothelial cells in vitro. Anticancer Res 2003;23:3199-206
   PubMed Web of Science ®Google Scholar
• Parkins CS, Holder AJ, Hill SA, et al. Determinants of antivascular action by combretastatin A-4-phosphate: role of nitric oxide. Br J Cancer 2000;83:811-16
   PubMed Web of Science ®Google Scholar
• Hori K, Saito S, Nihei Y, et al. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999;90:1026-38
   PubMedGoogle Scholar
• Chiron MF, Attenot F, Lefranc C, et al. Effects of the tumor vasculature targeting agent, AVE8062A, on endothelial cells in vitro and in vivo. 94th AACR meeting, Washington, July 11-14, 2003; abstract 4878
   Google Scholar
• Guffroy M, Dally C, Vrignaud P, et al. Evaluation of tissue perfusion (tumor, spleen, heart) in mice after administration of AVE8062, a tumor vascular-targeting agent. 95th AACR meeting, Orlando, March 2004; abstract 4699
   Google Scholar
• Guffroy M, Dally C, Vrignaud P, et al. The tumor vascular-targeting agent AVE8062 induces tumor blood flow shut down and necrosis in an orthotopic model of colon cancer in mice. 96th AACR annual meeting, Anaheim, CA, 16 – 20 April 2005; abstract 3412
   Google Scholar
• Lejeune P, Hodge T, Vrignaud P, Bissery M-C. In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. 93rd AACR meeting, San Francisco, April 6 – 10, 2002; abstract 781
   Google Scholar
• Hori K, Sato S. Microvascular mechanism by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334-44
   PubMed Web of Science ®Google Scholar
• Jouannot E, Carrez C, Lassau N, et al. Demonstration in animal and human of AVE8062-induced tumor blood flow shutdown using dynamic contrast enhanced-ultrasonography (DCE-US). 98th AACR Annual Meeting. Los Angeles, CA, 14 – 18 April 2007; abstract LB-328
   Google Scholar
• Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062A using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008;43(2):100-11
   PubMed Web of Science ®Google Scholar
• Bissery M-C, Lejeune P, Vrignaud P. In vivo evaluation of AVE8062A, a compound active on the tumor vasculature. 93rd AACR meeting, San Francisco, 6 – 10 April 2002; abstract 780
   Google Scholar
• Nihei Y, Suga Y, Morinaga Y, et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999;90:1016-25
   PubMedGoogle Scholar
• Lejeune P, Hodge T, Vrignaud P, et al. In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. 93rd AACR Meeting; 2002
   Google Scholar
• Bissery M-C, Lejeune P, Vrignaud P. In vivo synergy between platinum and AVE8062A, a tumor vasculature targeting agent. 94th AACR meeting, Washington, July 11–14, 2003; abstract 4877
   Google Scholar
• Lejeune P, Vrignaud P, Goulaouic H, et al. In vivo synergy between docetaxel and AVE8062A, a tumor vasculature targeting agent. 96th AACR annual meeting, Anaheim, CA, 16 – 20 April 2005;46:abstract 3425
   Google Scholar
• Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007;67:9337-45
   PubMed Web of Science ®Google Scholar
• Archimbaud Y, Fraschini MC, Pellerin R, et al. Mouse plasma and tumor pharmacokinetics of AVE8062 a new combretastatine. 93rd AACR meeting, San Francisco, 6 – 10 April 2002; abstract 779
   Google Scholar
• Tolcher AW, Forero L, Celio P, et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8052A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. Proc Am Soc Clin Oncol 2003;22:abstract 834
   Google Scholar
• Soria JC, Sessa C, Perotti A, et al. A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. 99th AACR Annual Meeting; San Diego, CA, 12 – 16 April 2008; abstract 07-11
   Google Scholar
• Sessa C, Soria JC, Tolcher A, et al. A phase I safety, pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients with advanced solid tumors 7th TAT meeting, Amsterdam, 18 – 22 April 2009: abstract O36
   Google Scholar
• Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-8
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26:159-67
   PubMed Web of Science ®Google Scholar